Navigation Links
Maternal Blood Test Might Spot Birth Defects More Safely
Date:11/10/2011

By Alan Mozes
HealthDay Reporter

WEDNESDAY, Nov. 9 (HealthDay News) -- In what a team of scientists says is a first, the researchers appear to have successfully screened for a rare form of fetal abnormality by means of a completely noninvasive blood test.

By performing a DNA analysis on a blood sample from a prospective mother, the team was able to accurately identify a specific chromosomal irregularity called "fetal microdeletion syndrome" in the unborn child, reported investigators at the Magee-Womens Research Institute (MWRI) at the University of Pittsburgh Medical Center.

In so doing, the researchers indicated it may one day be possible to avoid the use of much more invasive -- and thereby riskier -- standard diagnostic techniques, such as amniocentesis.

"If a fetal anomaly is suspected, mothers are usually offered an invasive screening procedure," said David Peters, head of the MWRI team and an associate professor in the department of obstetrics, gynecology and reproductive sciences.

"But there is a pretty significant, if small, level of risk to the health of the fetus associated with those tests. So there's been a strong push to try and reduce that risk," he noted.

"So I think the most compelling point," said Peters, "is that we have been able to illustrate a proof of concept. We have shown that you can identify these sorts of abnormalities without having to collect a physical sample from the baby or the placenta."

Peters and his colleagues discussed their findings in a letter published in the Nov. 10 issue of the New England Journal of Medicine.

Although this may be the first such test for this particular type of defect, maternal blood tests are also being developed for other fetal anomalies such as Down syndrome, as reported by HealthDay earlier this year. That study, conducted by Greek researchers, was published in the March 6 online edition of Nature Medicine.

According to the March of Dimes, roughly one in every 150 American babies is born with a structural or numerical chromosomal abnormality.

Such abnormalities can develop during egg or sperm cell growth, both before and after conception. Oftentimes they give rise to severe mental or physical defects, including Down syndrome and spina bifida.

Typically, chromosomal abnormalities are first identified during pregnancy by invasive diagnostic procedures.

Chorionic villus sampling is one option, involving the extraction of cellular material found in tiny finger-shaped growths located in the placenta. The procedure requires a catheter or long needle, and is usually conducted in the latter part of the first trimester.

The other option is amniocentesis, involving the extraction of a small amount of amniotic fluid surrounding the fetus for subsequent DNA analysis. The procedure is usually performed during the second trimester, and entails the use of a local anesthetic and the insertion of a needle through the mother's abdominal wall, uterus and amniotic sac.

But these invasive methods involve some risk, as fetal limb damage, fetal respiratory distress and even miscarriage can occur as a result.

To explore the potential of a less-invasive screening tool, the MWRI team focused on a couple who had already previously had a child born with physical and developmental abnormalities. In that case, the culprit was the absence (or "deletion") of specific chromosomal DNA, a condition that the child had inherited from his father.

At 21 weeks into her current pregnancy, the mother underwent traditional amniocentesis, which confirmed that her unborn child also suffered from the same rare fetal microdeletion syndrome.

In turn, at 35 weeks into the pregnancy the team drew a maternal blood sample and conducted a series of high-tech genetic sequencing tests. This time, no fetal tissue or blood was extracted.

The result: The non-invasive blood test successfully arrived at the same diagnosis as the invasive amniocentesis.

Peters acknowledged that the 35-week mark is late for prenatal screenings, but added that the time frame was appropriate for a comparative analysis of a new screening approach that is still in its infancy.

"I'm not a clinician, but I think it's fair to say that at this point we're a long way away from having something that would practically be able to replace amniocentesis," he cautioned.

Dr. De-Kun Li, a reproductive and perinatal epidemiologist in the division of research at Kaiser Permanente Northern California, in Oakland, said that while the risk associated with invasive screening is very low, an equally accurate risk-free blood test would be ideal.

"I believe the risk of spontaneous abortion or miscarriage due to an amniocentesis is 0.5 percent," he noted. "And the rate has been going down, because we are now much more technologically savvy. But of course a blood test would be noninvasive, cheaper and less risky. The question is, will the accuracy be the same? If so, then of course we'll go with the blood test. No questions asked. But that's a big 'if.'"

More information

For more on birth defects and chromosomal abnormalities, visit the March of Dimes.

SOURCES: David Peters, Ph.D., associate professor, department of obstetrics, gynecology and reproductive sciences, Magee-Womens Research Institute, University of Pittsburgh; De-Kun Li, M.D., Ph.D., M.P.H., reproductive and perinatal epidemiologist, division of research, Kaiser Permanente Northern California, Oakland, Calif.; Nov. 10, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Christy Turlington Burns to speak on energizing and broadening the Maternal Health movement
2. Harvard School of Public Health awarded $12 million grant to improve global maternal health
3. Maternal Blood Test Can Determine Sex of Fetus at 7 Weeks
4. NICHD renews maternal-fetal medicine, neonatal ties with Women & Infants
5. Society for Maternal-Fetal Medicine commends FDA on makena announcement
6. Online map of maternal health to inform world leaders
7. Citywide smoking ban contributes to significant decrease in maternal smoking, pre-term births
8. International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health
9. Closing the science-to-policy gap in maternal and child health in Africa
10. Country action is needed for maternal and child health in Africa
11. Full reproductive and sexual health rights essential for maternal health goals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Maternal Blood Test Might Spot Birth Defects More Safely
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the American ... particularly good news for prostate cancer patients: incidents of cancer is down as is ... report the cancer death rate has dropped from its peak of 215.1 in 1991 ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... officially unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience ... Taza Agua is renowned for introducing the world’s first untouched bottled water purposed ...
(Date:1/24/2017)... ... 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs Reclaimed”: an ... gossip, prostitution, adultery, anger, and common sense. , “Choosing Wisdom-Solomon’s Proverbs Reclaimed” ... David Coats. In September of 1983, they flew to Haiti to focus on ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... “The Octagon ... balance. “The Octagon of Spiritual Balances” is the creation of published author, Pastor Bernard ... Bernard J. Weathers holds a bachelor degree in religious education and a master degree ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 23, 2017 Optoelectronic components have the ... The interaction of these components with light makes ... range of applications. These components are primarily used ... and healthcare among others. Growing application ... low power consumption, reliability, scalability, and performance is ...
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted ... expected to grow at a CAGR of 6.0% during ... larger share in the global market between the two ... the hospital segment accounted for the highest share in ... peripheral I.V. catheter market is witnessing high growth rate, ...
(Date:1/23/2017)... Jan. 23, 2017  HOPE BIOSCIENCES announced today ... develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through ... pharmaceutical company. nuc -Gemcitabine consists ... surface nucleolin found on many cancer cells, and ... (antibody drug conjugates) or SMDCs (small molecule drug ...
Breaking Medicine Technology: